<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01096771</url>
  </required_header>
  <id_info>
    <org_study_id>Lipids for ARDS</org_study_id>
    <nct_id>NCT01096771</nct_id>
  </id_info>
  <brief_title>The Effect of Intravenous Lipids on Lung Function in Acute Respiratory Distress Syndrome (ARDS)</brief_title>
  <official_title>The Effect of Intravenous Lipid Emulsions on Lung Function in ARDS: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Research Institute, Indianapolis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Methodist Research Institute, Indianapolis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of nutritional supplementation with
      omega-9 &quot;olive-oil&quot; and omega-6 &quot;soybean oil&quot; based lipid emulsions in the Acute Respiratory
      Distress Syndrome (ARDS). The investigators hypothesize that these specific lipids in
      combination will immunomodulate the inflammatory reaction that occurs in the lungs of ARDS
      subjects. This concept is known as &quot;Pharmaconutrition.&quot; These lipids will be given
      intravenously so as to assure administration and only as a supplement to enteral nutrition
      which all subjects will also receive. The omega-9 will be compared to the omega-6 formulation
      which is the only FDA approved formulation of use in the United States since its development
      in 1961 by Fresenius-Kabi, Bad Homburg, Germany. The investigators plan to perform a
      bronchoscopy with lavage within 24 hours of enrollment, begin the lipid administration and
      continue it for 96 hours after which time the investigators will repeat bronchoscopy with
      lavage to assess changes. The lipid administration will cease following the second
      bronchoscopy. The fluid obtained from lavage combined with serum samples obtained at the time
      of bronchoscopy will be analyzed for inflammatory mediators and cell counts. Clinical data
      tracing will include but not be limited to: ventilator days, nutritional status, ICU time,
      oxygenation and lung compliance, and 30-day mortality.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to secure product from international source, low recruitment rate.
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bronchoalveolar Lavage Fluid Interleukin-8 Concentrations</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator Days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaO2:FiO2 Ratio</measure>
    <time_frame>4 days</time_frame>
    <description>PaO2:FiO2 ratio at time of 2nd Bronchoalveolar Lavage (BAL) or end of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 Day Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Infection</measure>
    <time_frame>30 days</time_frame>
    <description>We will use standard clinical criteria including but not limited to: fever, pyuria, new inflitrate on chest x-ray, positive blood cultures, abscess detected on imaging, leukocytosis, and positive skin or soft-tissue cultures to identify presence of new bacterial infections occurring after enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ Failures</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers (C-reactive Protein)</measure>
    <time_frame>96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allergic Reactions</measure>
    <time_frame>96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypertriglyceridemia</measure>
    <time_frame>96 hours</time_frame>
    <description>Defined as triglyceride level &gt;400</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>ClinOleic 20%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>96 hour continuous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intralipid 20%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>96 hour continuous infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ClinOleic 20%</intervention_name>
    <description>96 hour continuous infusion.</description>
    <arm_group_label>ClinOleic 20%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid 20%</intervention_name>
    <description>96 hour continuous infusion.</description>
    <arm_group_label>Intralipid 20%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed with predisposing condition causing ARDS

          -  are mechanically ventilated through an endotracheal tube

          -  have enteral feeding access

          -  have central venous access

          -  have a PaO2:FiO2 ratio of less than 200

          -  have bilateral pulmonary infiltrates on chest x-ray

        Exclusion Criteria:

          -  sedation requiring the use of diprivan (after enrollment)

          -  a clinical diagnosis of left ventricular failure

          -  lung cancer

          -  hematologic malignancy

          -  severe dyslipidemia

          -  condition precluding bronchoscopy including inability to maintain oxygen saturations
             greater than 90% per pulse oximetry despite conventional mechanical ventilation

          -  severe immunosuppression

          -  use of NSAIDS within previous 24 hours

          -  HIV positive

          -  pregnancy

          -  hypersensitivity to egg or soybean oil

          -  active myocardial infarction

          -  acute pancreatitis if complicated by hypertriglyceridemia

          -  severe sepsis with 2 or more organ failures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Naum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2010</study_first_submitted>
  <study_first_submitted_qc>March 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2010</study_first_posted>
  <results_first_submitted>March 26, 2014</results_first_submitted>
  <results_first_submitted_qc>April 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 26, 2014</results_first_posted>
  <last_update_submitted>April 25, 2014</last_update_submitted>
  <last_update_submitted_qc>April 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Methodist Research Institute, Indianapolis</investigator_affiliation>
    <investigator_full_name>W. Graham Carlos</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>Parenteral</keyword>
  <keyword>Pharmaconutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental ClinOleic 20%</title>
          <description>Patients received dietary supplement with ClinOleic 20%.</description>
        </group>
        <group group_id="P2">
          <title>Control: Intralipid 20%</title>
          <description>Patients received dietary supplement with Intralipid 20%.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental ClinOleic 20%</title>
          <description>Patients received dietary supplement with ClinOleic 20%.</description>
        </group>
        <group group_id="B2">
          <title>Control: Intralipid 20%</title>
          <description>Patients received dietary supplement with Intralipid 20%.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="11.24"/>
                    <measurement group_id="B2" value="60" spread="14.55"/>
                    <measurement group_id="B3" value="62" spread="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bronchoalveolar Lavage Fluid Interleukin-8 Concentrations</title>
        <time_frame>96 hours</time_frame>
        <population>Each arm has one less subject than specified in the participate flow module. One is secondary to the fact that the subject refused the 2nd bronchoscopy and the other is because the primary physician felt the subject was too sick to undergo the 2nd bronchscopy.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental ClinOleic 20%</title>
            <description>Patients received dietary supplement with ClinOleic 20%.</description>
          </group>
          <group group_id="O2">
            <title>Control: Intralipid 20%</title>
            <description>Patients received dietary supplement with Intralipid 20%.</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchoalveolar Lavage Fluid Interleukin-8 Concentrations</title>
          <population>Each arm has one less subject than specified in the participate flow module. One is secondary to the fact that the subject refused the 2nd bronchoscopy and the other is because the primary physician felt the subject was too sick to undergo the 2nd bronchscopy.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1092" spread="1017"/>
                    <measurement group_id="O2" value="544" spread="453.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator Days</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental ClinOleic 20%</title>
            <description>Patients received dietary supplement with ClinOleic 20%.</description>
          </group>
          <group group_id="O2">
            <title>Control: Intralipid 20%</title>
            <description>Patients received dietary supplement with Intralipid 20%.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator Days</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="10.11"/>
                    <measurement group_id="O2" value="18" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PaO2:FiO2 Ratio</title>
        <description>PaO2:FiO2 ratio at time of 2nd Bronchoalveolar Lavage (BAL) or end of study drug administration.</description>
        <time_frame>4 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental ClinOleic 20%</title>
            <description>Patients received dietary supplement with ClinOleic 20%.</description>
          </group>
          <group group_id="O2">
            <title>Control: Intralipid 20%</title>
            <description>Patients received dietary supplement with Intralipid 20%.</description>
          </group>
        </group_list>
        <measure>
          <title>PaO2:FiO2 Ratio</title>
          <description>PaO2:FiO2 ratio at time of 2nd Bronchoalveolar Lavage (BAL) or end of study drug administration.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159" spread="60.8"/>
                    <measurement group_id="O2" value="149" spread="78.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30 Day Mortality</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental ClinOleic 20%</title>
            <description>Patients received dietary supplement with ClinOleic 20%.</description>
          </group>
          <group group_id="O2">
            <title>Control: Intralipid 20%</title>
            <description>Patients received dietary supplement with Intralipid 20%.</description>
          </group>
        </group_list>
        <measure>
          <title>30 Day Mortality</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Infection</title>
        <description>We will use standard clinical criteria including but not limited to: fever, pyuria, new inflitrate on chest x-ray, positive blood cultures, abscess detected on imaging, leukocytosis, and positive skin or soft-tissue cultures to identify presence of new bacterial infections occurring after enrollment.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental ClinOleic 20%</title>
            <description>Patients received dietary supplement with ClinOleic 20%.</description>
          </group>
          <group group_id="O2">
            <title>Control: Intralipid 20%</title>
            <description>Patients received dietary supplement with Intralipid 20%.</description>
          </group>
        </group_list>
        <measure>
          <title>New Infection</title>
          <description>We will use standard clinical criteria including but not limited to: fever, pyuria, new inflitrate on chest x-ray, positive blood cultures, abscess detected on imaging, leukocytosis, and positive skin or soft-tissue cultures to identify presence of new bacterial infections occurring after enrollment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Organ Failures</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental ClinOleic 20%</title>
            <description>Patients received dietary supplement with ClinOleic 20%.</description>
          </group>
          <group group_id="O2">
            <title>Control: Intralipid 20%</title>
            <description>Patients received dietary supplement with Intralipid 20%.</description>
          </group>
        </group_list>
        <measure>
          <title>Organ Failures</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers (C-reactive Protein)</title>
        <time_frame>96 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental ClinOleic 20%</title>
            <description>Patients received dietary supplement with ClinOleic 20%.</description>
          </group>
          <group group_id="O2">
            <title>Control: Intralipid 20%</title>
            <description>Patients received dietary supplement with Intralipid 20%.</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarkers (C-reactive Protein)</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="9.06"/>
                    <measurement group_id="O2" value="13" spread="13.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental ClinOleic 20%</title>
            <description>Patients received dietary supplement with ClinOleic 20%.</description>
          </group>
          <group group_id="O2">
            <title>Control: Intralipid 20%</title>
            <description>Patients received dietary supplement with Intralipid 20%.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="8.45"/>
                    <measurement group_id="O2" value="28" spread="19.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Allergic Reactions</title>
        <time_frame>96 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental ClinOleic 20%</title>
            <description>Patients received dietary supplement with ClinOleic 20%.</description>
          </group>
          <group group_id="O2">
            <title>Control: Intralipid 20%</title>
            <description>Patients received dietary supplement with Intralipid 20%.</description>
          </group>
        </group_list>
        <measure>
          <title>Allergic Reactions</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypertriglyceridemia</title>
        <description>Defined as triglyceride level &gt;400</description>
        <time_frame>96 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental ClinOleic 20%</title>
            <description>Patients received dietary supplement with ClinOleic 20%.</description>
          </group>
          <group group_id="O2">
            <title>Control: Intralipid 20%</title>
            <description>Patients received dietary supplement with Intralipid 20%.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypertriglyceridemia</title>
          <description>Defined as triglyceride level &gt;400</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental ClinOleic 20%</title>
          <description>Patients received dietary supplement with ClinOleic 20%.</description>
        </group>
        <group group_id="E2">
          <title>Control: Intralipid 20%</title>
          <description>Patients received dietary supplement with Intralipid 20%.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Patient died after study infusion drug completed. Mortality rate for ARDS is &gt;25%. While this is a SAE it is not unexpected and could not be directly connected to study experimental or control drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>New Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <description>An adverse event was considered a rise in the serum creatinine level while on the study experimental or control drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. William Carlos</name_or_title>
      <organization>Indiana University School of Medicine</organization>
      <phone>3178807819</phone>
      <email>wcarlos@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

